Bevacizumab (bev), when added to a moderate dose combination of previously failed cytotoxins, as a third- and fourth-line therapy for refractory gastric, cholangiocarcinoma, and ovarian cancers, produced high-quality responses.
Background: Therapeutic cancer vaccination is an area of interest, even though promising efficacy has not been demonstrated so far.
The Lancet has published a peer-reviewed article detailing the successful results of a phase IIb trial with VGX 3100 vaccine,...
Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries.
Renal cell cancer (RCC) is the tenth most common malignancy in adults. In recent years, several approaches of active and passive immunotherapy have been studied extensively in clinical trials of patients with RCC.
Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases.
Merck Inc., and IAVI ( International AIDS Vaccine Initiative), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop an investigational vaccine against SARS-CoV-2 to be used for the prevention of COVID-19.
First ever ESMO Clinical Practice Guideline in Gestational Trophoblastic Disease features incidence and epidemiology of a spectrum of disorders from pre-malignant conditions to malignant forms of the disease.
Scientists at Stanford are believed to be the first to have discovered a biomarker that can predict who will be most susceptible to influenza.
A new study from Stanford University may have found another use for iPS cells: priming the immune system to attack tumours.